Satoshi Yasuda

Dr. Satoshi Yasuda

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2015 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SNSatoshi Nishiwada
Satoshi Nishiwada
MSMasayuki Sho
Masayuki Sho
SYSatoshi Yasuda
Satoshi Yasuda
KSKeiji Shimada
Keiji Shimada
IYIchiro Yamato
Ichiro Yamato
YNYoshiyuki Nakajima
Yoshiyuki Nakajima
Nectin-4 belongs to the nectin family that has diverse physiological and pathological functions in humans. Recent studies have also suggested some roles for Nectin-4 in several human cancers. However, the precise roles and clinical relevance of Nectin-4 in tumors are largely unknown. Nectin-4 expression was investigated in 123 patients with pancreatic cancer by immunohistochemistry. Furthermore, we investigated the association of Nectin-4 in pancreatic cancer with tumor proliferation, angiogenesis and immunity by using immunohistochemistry and siRNA interference method. Patients with high Nectin-4 expression had poorer postoperative prognosis than those with low expression. Importantly, multivariate analysis indicated that Nectin-4 expression had a significant independent prognostic value in pancreatic cancer (HR = 1.721, 1.085-2.730; P = 0.021). Tumor Nectin-4 expression was significantly correlated with Ki67 expression. In addition, siRNA-mediated gene silencing of Nectin-4 significantly inhibited the cell proliferation in human pancreatic cancer cells, Capan-2 and BxPC-3. Furthermore, Nectin-4 expression was also positively correlated with VEGF expression and intratumoral microvessel density. However, there were no significant correlations of tumor Nectin-4 expression with tumor-infiltrating T cells. Nectin-4 is a significant prognostic predictor, and may play a critical role in pancreatic cancer. Nectin-4 may be novel therapeutic target for pancreatic cancer.

15 September 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
IYIchiro Yamato
Ichiro Yamato
MSMasayuki Sho
Masayuki Sho
KSKeiji Shimada
Keiji Shimada
KHKiyohiko Hotta
Kiyohiko Hotta
YUYuko Ueda
Yuko Ueda
YNYoshiyuki Nakajima
Yoshiyuki Nakajima
The PCA-1/ALKBH3 gene implicated in DNA repair is expressed in several human malignancies but its precise contributions to cancer remain mainly unknown. In this study, we have determined its functions and clinical importance in pancreatic cancer. PCA-1/ALKBH3 functions in proliferation, apoptosis and angiogenesis were evaluated in human pancreatic cancer cells in vitro and in vivo. Further, PCA-1/ALKBH3 expression in 116 patients with pancreatic cancer was evaluated by immunohistochemistry. siRNA-mediated silencing of PCA-1/ALKBH3 expression induced apoptosis and suppressed cell proliferation. Conversely, overexpression of PCA-1/ALKBH3 increased anchorage-independent growth and invasiveness. In addition, PCA-1/ALKBH3 silencing downregulated VEGF expression and inhibited angiogenesis in vivo. Furthermore, immunohistochemical analysis showed that PCA-1/ALKBH3 expression was abundant in pancreatic cancer tissues, where it correlated with advanced tumor status, pathological stage and VEGF intensity. Importantly, patients with low positivity of PCA-1/ALKBH3 expression had improved postoperative prognosis compared with those with high positivity. Our results establish PCA-1/ALKBH3 as important gene in pancreatic cancer with potential utility as a therapeutic target in this fatal disease. Cancer Res; 72(18); 4829–39. ©2012 AACR.

18 September 2024 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
SYSatoshi Yasuda
Satoshi Yasuda
YMYasuko Matsuo
Yasuko Matsuo
SDShunsuke Doi
Shunsuke Doi
TSTakeshi Sakata
Takeshi Sakata
MNMinako Nagai
Minako Nagai
MSMasayuki Sho
Masayuki Sho

16 October 2023 in Pancreatology
Verified
Journal Article
Closed access
TTTaichi Terai
Taichi Terai
MNMinako Nagai
Minako Nagai
KNKota Nakamura
Kota Nakamura
YKYuichiro Kohara
Yuichiro Kohara
SYSatoshi Yasuda
Satoshi Yasuda
MSMasayuki Sho
Masayuki Sho

1 June 2023 in Pancreatology
Verified
Journal Article
Closed access
MNMinako Nagai
Minako Nagai
KNKota Nakamura
Kota Nakamura
TTTaichi Terai
Taichi Terai
YKYuichiro Kohara
Yuichiro Kohara
SYSatoshi Yasuda
Satoshi Yasuda
MSMasayuki Sho
Masayuki Sho

7 March 2025 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
SYSatoshi Yasuda
Satoshi Yasuda
MNMinako Nagai
Minako Nagai
KNKota Nakamura
Kota Nakamura
YMYasuko Matsuo
Yasuko Matsuo
MSMasayuki Sho
Masayuki Sho
This review discusses the evolving role of radiotherapy (RT) in the surgical treatment of pancreatic ductal adenocarcinoma (PDAC). Despite advancements in multidisciplinary treatment, PDAC continues to present significant challenges in surgical treatment strategies. Neoadjuvant therapy, in combination with chemotherapy and RT, aims to improve patient outcomes by reducing tumor size, controlling local spread, and eradicating micrometastatic disease that cannot be detected at the time of diagnosis. Recent randomized trials have shown that both neoadjuvant chemoradiotherapy (NACRT) and neoadjuvant chemotherapy (NAC) improve surgical outcomes compared with upfront surgery. A network meta‐analysis integrating multiple trials demonstrated that NACRT significantly improves overall survival compared to NAC (HR: 0.79, 95% CI: 0.64–0.98). NACRT has also shown advantage in local tumor control. For locally advanced PDAC, the role of RT in conversion therapy is being actively investigated. The integration of RT in treatment regimens requires careful consideration of its therapeutic benefits against potential adverse effects. Although experimental studies suggest potential immunological benefits of RT, clinical validation remains incomplete. Recent advances in radiation delivery techniques have improved the therapeutic ratio, although further clinical validation is needed. The optimal sequence and combination of these treatment modalities with surgical strategies continue to be evaluated in ongoing clinical trials. This review synthesizes evidence from recent clinical trials and previous studies to evaluate the effectiveness, challenges, and potential of RT in PDAC treatment, aiming to inform both current clinical practice and future research directions.